NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature

Neuro-Oncology

Volumn 13, Issue 8, 2011, Pages 830-845

  Al Mayhani, M Talal F ^a   Grenfell, Richard ^b   Narita, Masashi ^b   Piccirillo, Sara ^a   Kenney Herbert, Emma ^a   Fawcett, James W ^a   Collins, Peter V ^b   Ichimura, Koichi ^b   Watts, Colin ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Glioblastoma; Molecular signature; NG2; Progenitor; Proliferation

Indexed keywords

BRAIN PROTEIN; CELL CYCLE PROTEIN; LEUCINE ZIPPER PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN; NEUROGLIA 2 PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CELL POPULATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED ICR; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 80052740275     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor088     Document Type: Article

References (107)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
2. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5(3):198-206. (Pubitemid 40873035)
3. Walker MD. The contemporary role of chemotherapy in the treatment of malignant brain tumor. Clin Neurosurg. 1978;25:388-396.
4. Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333-343. (Pubitemid 9013313)
5. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
6. Stallcup WB, Huang FJ. A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr. 2008;2(3):192-201.
7. Dawson MR, Polito A, Levine JM, Reynolds R. NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci. 2003;24(2): 476-488. (Pubitemid 37311310)
8. Dimou L, Simon C, Kirchhoff F, Takebayashi H, Gotz M. Progeny of Olig2-expressing progenitors in the gray and white matter of the adult mouse cerebral cortex. J Neurosci. 2008;28(41):10434-10442.
9. Geha S, Pallud J, Junier MP, et al. NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain. Brain Pathol. 2010;20(2):399-411.
10. Gensert JM, Goldman JE. Heterogeneity of cycling glial progenitors in the adult mammalian cortex and white matter. J Neurobiol. 2001;48(2):75-86. (Pubitemid 32645825)
11. Goldman SA, Sim F. Neural progenitor cells of the adult brain. In: Stem Cells: Nuclear Reprogramming and Therapeutic Applications. Vol 265. New York, NY: John Wiley & Sons, Ltd; 2005.
12. Rivers LE, Young KM, Rizzi M, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci. 2008;11(12):1392-1401.
13. Tang DG, Tokumoto YM, Apperly JA, Lloyd AC, Raff MC. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science. 2001;291(5505):868-871. (Pubitemid 32120756)
14. Zhu X, Bergles DE, Nishiyama A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development. 2008;135(1): 145-157. (Pubitemid 351201488)
15. Buffo A, Vosko MR, Erturk D, et al. Expression pattern of the transcription factor Olig2 in response to brain injuries: implications for neuronal repair. Proc Natl Acad Sci U S A. 2005;102(50):18183-18188. (Pubitemid 41798522)
16. Fancy SP, Zhao C, Franklin RJ. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Mol Cell Neurosci. 2004;27(3): 247-254. (Pubitemid 39433839)
17. Zawadzka M, Rivers LE, Fancy SP, et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell. 2010;6(6): 578-590.
18. Zhao JW, Raha-Chowdhury R, Fawcett JW, Watts C. Astrocytes and oligodendrocytes can be generated from NG2+ progenitors after acute brain injury: intracellular localization of oligodendrocyte transcription factor 2 is associated with their fate choice. Eur J Neurosci. 2009;29(9):1853-1869.
19. Berry M, Hubbard P, Butt AM. Cytology and lineage of NG2-positive glia. J Neurocytol. 2002;31(6-7):457-467. (Pubitemid 37378258)
20. Chandran S, Hunt D, Joannides A, Zhao C, Compston A, Franklin RJ. Myelin repair: the role of stem and precursor cells in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci. 2008;363(1489):171-183. (Pubitemid 350174574)
21. Nishiyama A, Komitova M, Suzuki R, Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci. 2009;10(1):9-22.
22. Levine JM, Stallcup WB. Plasticity of developing cerebellar cells in vitro studied with antibodies against the NG2 antigen. J Neurosci. 1987;7(9):2721-2731.
23. Marconi S, De Toni L, Lovato L, et al. Expression of gangliosides on glial and neuronal cells in normal and pathological adult human brain. J Neuroimmunol. 2005;170(1-2):115-121. (Pubitemid 41740912)
24. Pringle NP, Mudhar HS, Collarini EJ, Richardson WD. PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. Development. 1992;115(2):535-551.
25. Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 1983;303(5916):390-396. (Pubitemid 13094875)
26. Raff MC, Miller RH, Noble M. Glial cell lineages in the rat optic nerve. Cold Spring Harb Symp Quant Biol. 1983;48(Pt 2):569-572.
27. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20(17):6404-6412.
28. Gogate N, Verma L, Zhou JM, et al. Plasticity in the adult human oligodendrocyte lineage. J Neurosci. 1994;14(8):4571-4587. (Pubitemid 24237884)
29. Kennedy PG, Fok-Seang J. Studies on the development, antigenic phenotype and function of human glial cells in tissue culture. Brain. 1986;109(Pt 6):1261-1277. (Pubitemid 17212990)
30. Nunes MC, Roy NS, Keyoung HM, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med. 2003;9(4):439-447. (Pubitemid 36460078)
31. Mori T, Wakabayashi T, Takamori Y, Kitaya K, Yamada H. Phenotype analysis and quantification of proliferating cells in the cortical gray matter of the adult rat. Acta Histochem Cytochem. 2009;42(1):1-8.
32. Colin C, Baeza N, Tong S, et al. In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathol Appl Neurobiol. 2006;32(2):189-202.
33. Fael Al-Mayhani TM, Ball SL, Zhao JW, et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. Journal of neuroscience methods. 2009;176(2):192-199.
34. Fiegler H, Carr P, Douglas EJ, et al. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes, Chromosomes & Cancer. 2003;36(4): 361-374. (Pubitemid 36314519)
35. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991;3(7):207-212.
36. Hodgson JG, Yeh RF, Ray A, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol. 2009;11(5):477-487.
37. Horvath S, Zhang B, Carlson M, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A. 2006;103(46):17402-17407. (Pubitemid 44788981)
38. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173. (Pubitemid 43357943)
39. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002;13(6):1977-2000. (Pubitemid 34651487)
40. Petalidis LP, Oulas A, Backlund M, et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther. 2008;7(5):1013-1024.
41. Butt AM, Hamilton N, Hubbard P, Pugh M, Ibrahim M. Synantocytes: the fifth element. J Anat. 2005;207(6):695-706. (Pubitemid 43019729)
42. Ozerdem U, Grako KA, Dahlin-Huppe K, Monosov E, Stallcup WB. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn. 2001;222(2):218-227. (Pubitemid 32937594)
43. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. The Journal of Clinical Investigation. 1973;52(11):2745-2756.
44. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46(2): 185-190. (Pubitemid 16031685)
45. D'Amore PA, Smith SR. Growth factor effects on cells of the vascular wall: a survey. Growth Factors. 1993;8(1):61-75. (Pubitemid 23093212)
46. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277(5323):242-245. (Pubitemid 27446080)
47. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res. 2002;63(1): 129-134. (Pubitemid 34971515)
48. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, Gladson CL. Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res. 1991;51(18):4986-4993.
49. He J, Liu Y, Xie X, et al. Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J Proteome Res. 2010;9(5):2565-2572.
50. Chekenya M, Krakstad C, Svendsen A, et al. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 2008;27(39): 5182-5194.
51. Wiranowska M, Ladd S, Smith SR, Gottschall PE. CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain cell biology. 2006;35(2-3):159-172. (Pubitemid 47630628)
52. Brekke C, Lundervold A, Enger PO, et al. NG2 expression regulates vascular morphology and function in human brain tumours. Neuroimage. 2006;29(3):965-976. (Pubitemid 43121220)
53. Facoetti A, Ranza E, Grecchi I, et al. Immunohistochemical evaluation of minichromosome maintenance protein 7 in astrocytoma grading. Anticancer Res. 2006;26(5A):3513-3516. (Pubitemid 44701531)
54. Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett. 2008;263(2):157-163.
55. Marie SK, Okamoto OK, Uno M, et al. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer. 2008;122(4):807-815.
56. Nakano I, Masterman-Smith M, Saigusa K, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 2008;86(1):48-60.
57. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
58. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193-204. (Pubitemid 351301852)
59. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316-323. (Pubitemid 39551659)
60. Short SC, Martindale C, Bourne S, Brand G, Woodcock M, Johnston P. DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro Oncol. 2007;9(4):404-411.
61. Xiong J, Wang Y, Zhu Z, et al. NG2 proteoglycan increases mesangial cell proliferation and extracellular matrix production. Biochem Biophys Res Commun. 2007;361(4):960-967. (Pubitemid 47259029)
62. Kucharova K, Stallcup WB. The NG2 proteoglycan promotes oligodendrocyte progenitor proliferation and developmental myelination. Neuroscience. 2010;166(1):185-194.
63. Makagiansar IT, Williams S, Mustelin T, Stallcup WB. Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol. 2007;178(1):155-165. (Pubitemid 47026410)
64. Grako KA, Ochiya T, Barritt D, Nishiyama A, Stallcup WB. PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci. 1999;112(Pt 6):905-915. (Pubitemid 29179323)
65. Goretzki L, Burg MA, Grako KA, Stallcup WB. High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem. 1999;274(24):16831-16837.
66. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res. 1996;43(3):299-314. (Pubitemid 26054018)
67. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neurosci Res. 1996;43(3):315-330. (Pubitemid 26054019)
68. Chatterjee N, Stegmuller J, Schatzle P, et al. Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells. J Biol Chem. 2008;283(13):8310-8317.
69. Hayakawa-Yano Y, Nishida K, Fukami S, et al. Epidermal growth factor signaling mediated by grb2 associated binder1 is required for the spatiotemporally regulated proliferation of olig2-expressing progenitors in the embryonic spinal cord. Stem Cells. 2007;25(6):1410-1422. (Pubitemid 47106008)
70. Makagiansar IT, Williams S, Dahlin-Huppe K, Fukushi J, Mustelin T, Stallcup WB. Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J Biol Chem. 2004;279(53):55262-55270. (Pubitemid 40066523)
71. Yang J, Price MA, Neudauer CL, et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol. 2004;165(6):881-891. (Pubitemid 38821978)
72. Wang X, Osada T, Wang Y, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst. 2010;102(19):1496-1512.
73. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol. 1998;177(2):299-312. (Pubitemid 28452831)
74. Leger O, Johnson-Leger C, Jackson E, Coles B, Dean C. The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. Int J Cancer. 1994;58(5):700-705. (Pubitemid 24279434)
75. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood. 1996;87(3):1134-1139.
76. Hilden JM, Smith FO, Frestedt JL, et al. MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood. 1997;89(10):3801-3805. (Pubitemid 27227105)
77. Mauvieux L, Delabesse E, Bourquelot P, et al. NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Br J Haematol. 1999;107(3):674-676.
78. Smith FO, Rauch C, Williams DE, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood. 1996;87(3):1123-1133.
79. Zangrando A, Intini F, te Kronnie G, Basso G. Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study. Leukemia. 2008;22(4):858-861. (Pubitemid 351552637)
80. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
81. Bulloch K, Stallcup WB, Cohn M. The derivation and characterization of neuronal cell lines from rat and mouse brain. Brain research. 1977;135(1):25-36. (Pubitemid 8194348)
82. Johansson FK, Goransson H, Westermark B. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene. 2005;24(24):3896-3905. (Pubitemid 40896401)
83. Wilson SS, Baetge EE, Stallcup WB. Antisera specific for cell lines with mixed neuronal and glial properties. Dev Biol. 1981;83(1):146-153.
84. Shoshan Y, Nishiyama A, Chang A, et al. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A. 1999;96(18):10361-10366. (Pubitemid 29422563)
85. Aguirre-Cruz L, Mokhtari K, Hoang-Xuan K, et al. Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol. 2004;67(3):265-271. (Pubitemid 39137356)
86. Marie Y, Sanson M, Mokhtari K, et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet. 2001;358(9278):298-300. (Pubitemid 32738972)
87. Lu QR, Park JK, Noll E, et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A. 2001;98(19):10851-10856. (Pubitemid 32878708)
88. Mokhtari K, Paris S, Aguirre-Cruz L, et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol. 2005;31(1):62-69. (Pubitemid 40222826)
89. Bannykh SI, Stolt CC, Kim J, Perry A, Wegner M. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol. 2006;76(2):115-127. (Pubitemid 43135844)
90. Bouvier C, Bartoli C, Aguirre-Cruz L, et al. Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. J Neurosurg. 2003;99(2):344-350. (Pubitemid 36903275)
91. Ikota H, Kinjo S, Yokoo H, Nakazato Y. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol. 2006;111(5):475-482.
92. Ligon KL, Alberta JA, Kho AT, et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004;63(5):499-509. (Pubitemid 38669670)
93. Ohnishi A, Sawa H, Tsuda M, et al. Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. J Neuropathol Exp Neurol. 2003;62(10):1052-1059. (Pubitemid 37229534)
94. Riemenschneider MJ, Koy TH, Reifenberger G. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol. 2004;107(3):277-282. (Pubitemid 38263419)
95. Yokoo H, Nobusawa S, Takebayashi H, et al. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol. 2004;164(5):1717-1725. (Pubitemid 38529774)
96. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15(23):2755-2765. (Pubitemid 28004565)
97. Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992;52(11):3213-3219.
98. Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem. 1991;266(25): 16755-16763. (Pubitemid 21907863)
99. Nister M, Libermann TA, Betsholtz C, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res. 1988;48(14):3910-3918.
100. Colin C, Virard I, Baeza N, et al. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathol Appl Neurobiol. 2007;33(4): 431-439. (Pubitemid 47037890)
101. Rowitch DH, Kriegstein AR. Developmental genetics of vertebrate glialcell specification. Nature. 2010;468(7321):214-222.
102. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med. 2008;86(9):1025-1032.
103. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991): 568-571.
104. Chekenya M, Hjelstuen M, Enger PO, et al. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 2002;16(6):586-588.
105. Ozerdem U, Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis. 2004;7(3):269-276.
106. Long DM. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg. 1970;32(2):127-144.
107. Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J Neurosurg. 1996;85(6):1078-1084. (Pubitemid 26396562)